What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterol-lowering agents?

MOspace/Manakin Repository

Breadcrumbs Navigation

What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterol-lowering agents?

Please use this identifier to cite or link to this item: http://hdl.handle.net/10355/2824

[+] show full item record


Title: What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterol-lowering agents?
Author: Weismantel, David
Keywords: hypercholesterolemia
pharmacologic treatment
creatine kinase (CK)
aminotransferases
Date: 2001-11
Publisher: Family Physicians Inquiries Network
Abstract: Recommendations for measuring serum aminotransferase levels before initiating pharmacologic treatment for hypercholesterolemia, after 12 weeks of therapy, and periodically afterward are based on expert opinion. It is not recommended that serum creatine kinase (CK) levels be monitored for elevation indicative of myopathy during cholesterol-lowering therapy. (Grade of recommendation: D, based on expert opinion without explicit critical appraisal)
URI: http://hdl.handle.net/10355/2824

This item appears in the following Collection(s)

[+] show full item record